Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 2/20 | 0.62 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.51 |
| ▸ | HRH4 | Q9H3N8 | 6/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | DNM2 | P50570 | 2/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7522734 | 0.90 | TLR8 (0.65) | NUDT1TLR8HRH4ESR1ESR2 | |
| SCHEMBL9182270 | 0.86 | NUDT1 (0.66) | NUDT1TLR8HRH4CYP2D6CYP2C19 | |
| SCHEMBL7712160 | 0.83 | ESR1 (0.57) | NUDT1TLR8ESR1ESR2CYP2C19 | |
| SCHEMBL8585646 | 0.77 | TLR8 (0.81) | TLR8HRH4ESR1ESR2CYP2D6 | |
| SCHEMBL20109484 | 0.77 | NUDT1 (1.00) | NUDT1 | |
| SCHEMBL9651803 | 0.76 | TLR8 (0.63) | NUDT1TLR8HRH4CYP2D6CYP2C19 | |
| SCHEMBL8597545 | 0.76 | CYP2D6 (0.70) | TLR8HRH4ESR1ESR2CYP2D6 | |
| SCHEMBL1576638 | 0.73 | NUDT1 (0.65) | NUDT1HRH4HRH3 | |
| SCHEMBL21016705 | 0.72 | DNM2 (0.50) | HRH4ESR1ESR2CYP2D6CYP2C19 | |
| SCHEMBL9178127 | 0.72 | NUDT1 (0.66) | NUDT1HRH4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020103216-A1 | Administering topically a tyrosinase activity-stimulating amount of a 6-substituted pyrimidine 3-oxide | PRUCHE FRANCIS (FR) | 2002-08-01 | — | — | US | claimed |
| US-6380263-B1 | ADMINISTERING TO HUMAN EFFECTIVE TYROSINASE ACTIVITY-STIMULATING AMOUNT OF AT LEAST ONE 6-SUBSTITUTED PYRIMIDINE 3-OXIDE COMPOUND FOR PROMOTING PIGMENTATION OF THE SKIN AND/OR HAIR | SOCIETE L'OREAL (FR) | 2002-04-30 | — | — | US | claimed |
| EP-0519819-B1 | Composition for use to reduce hair loss and to induce and stimulate its growth, containing derivatives of 2,4,6-triaminopyrimidin-N-oxide and the new derivatives of 2,4,6-triaminopyrimidin-N-oxide | OREAL (FR) | 1995-07-19 | — | — | EP | claimed |
| EP-0519819-A1 | Composition for use to reduce hair loss and to induce and stimulate its growth, containing derivatives of 2,4,6-triaminopyrimidin-N-oxide and the new derivatives of 2,4,6-triaminopyrimidin-N-oxide | L'OREAL (FR) | 1992-12-23 | — | — | EP | claimed |
| EP-0736300-B1 | Use in a composition of a pyrimidine derivative substituted in position 6 as an activator and/or stabilizer of cyclooxygenase | OREAL (FR) | 2003-03-05 | — | — | EP | disclosed |
| EP-0519819-B1 | Composition for use to reduce hair loss and to induce and stimulate its growth, containing derivatives of 2,4,6-triaminopyrimidin-N-oxide and the new derivatives of 2,4,6-triaminopyrimidin-N-oxide | OREAL (FR) | 1995-07-19 | — | — | EP | disclosed |
| EP-0519819-A1 | Composition for use to reduce hair loss and to induce and stimulate its growth, containing derivatives of 2,4,6-triaminopyrimidin-N-oxide and the new derivatives of 2,4,6-triaminopyrimidin-N-oxide | L'OREAL (FR) | 1992-12-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103216-A1 | Administering topically a tyrosinase activity-stimulating amount of a 6-substituted pyrimidine 3-oxide | TYR, TH, MC1R | NUDT1 38/4885TLR8 3499/4885HRH4 412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.